You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial
|
|---|---|
| Published in |
Journal of Clinical Oncology, March 2016
|
| DOI | 10.1200/jco.2015.63.4691 |
| Pubmed ID | |
| Authors |
Ulrich Herrlinger, Niklas Schäfer, Joachim P Steinbach, Astrid Weyerbrock, Peter Hau, Roland Goldbrunner, Franziska Friedrich, Veit Rohde, Florian Ringel, Uwe Schlegel, Michael Sabel, Michael W Ronellenfitsch, Martin Uhl, Jaroslaw Maciaczyk, Stefan Grau, Oliver Schnell, Mathias Hänel, Dietmar Krex, Peter Vajkoczy, Rüdiger Gerlach, Rolf-Dieter Kortmann, Maximilian Mehdorn, Jochen Tüttenberg, Regine Mayer-Steinacker, Rainer Fietkau, Stefanie Brehmer, Frederic Mack, Moritz Stuplich, Sied Kebir, Ralf Kohnen, Elmar Dunkl, Barbara Leutgeb, Martin Proescholdt, Torsten Pietsch, Horst Urbach, Claus Belka, Walter Stummer, Martin Glas |
X Demographics
The data shown below were collected from the profiles of 14 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 36% |
| Unknown | 9 | 64% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 12 | 86% |
| Scientists | 2 | 14% |
Mendeley readers
The data shown below were compiled from readership statistics for 191 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | <1% |
| Spain | 1 | <1% |
| Unknown | 189 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 26 | 14% |
| Other | 22 | 12% |
| Student > Bachelor | 21 | 11% |
| Student > Ph. D. Student | 18 | 9% |
| Student > Master | 17 | 9% |
| Other | 32 | 17% |
| Unknown | 55 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 78 | 41% |
| Biochemistry, Genetics and Molecular Biology | 9 | 5% |
| Neuroscience | 9 | 5% |
| Agricultural and Biological Sciences | 8 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 4% |
| Other | 14 | 7% |
| Unknown | 66 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 29. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 September 2023.
All research outputs
#1,368,106
of 25,837,817 outputs
Outputs from Journal of Clinical Oncology
#3,377
of 22,362 outputs
Outputs of similar age
#22,600
of 316,672 outputs
Outputs of similar age from Journal of Clinical Oncology
#65
of 263 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,362 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.1. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 316,672 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 263 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.